Trastuzumab and Erlotinib as First-Line Therapy in Treating Women With Metastatic Breast Cancer Associated With HER2/Neu Overexpression

NCT00033514 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

27

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

BIOLOGICAL: trastuzumab
DRUG: erlotinib hydrochloride

Sponsor

Jonsson Comprehensive Cancer Center

Collaborators

[object Object]